Page 63 - HIVMED_v21_i1.indb

Page 37 of 39 Guideline

DRV/r darunavir/ritonavir TBM tuberculosis meningitis
DTG dolutegravir TC total cholesterol
eGFR estimated glomerular filtration rate TDF tenofovir disoproxil fumarate
ELISA enzyme-linked immunosorbent assay TG triglycerides
ETR etravirine TST tuberculin skin test
FBC full blood count ULN upper limit of normal
FTC emtricitabine VL viral load
GGT gamma-glutamyl transferase WHO World Health Organization
GI gastrointestinal WOCP women of childbearing potential
Hb haemoglobin
HBsAg hepatitis B surface antigen 31. References
HBV hepatitis B virus
HIV human immunodeficiency virus 1. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African
ICU intensive care unit adults starting antiretroviral treatment: Collaborative analysis of cohort studies.
PLoS Med. 2013;10(4):e1001418. https://doi.org/10.1371/journal.pmed.
INR international normalised ratio 2. 1001418
Maartens G. ‘Covering the tail’ after stopping efavirenz-based antiretroviral
InSTI integrase strand transfer inhibitor therapy. S Afr J HIV Med. 2020;21(1):a1036. https://doi.org/10.4102/sajhivmed.
v21i1.1036
IPT isoniazid preventive therapy 3. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B
LAM lipoarabinomannan virus resistance to lamivudine in human immunodeficiency virus-infected
patients. Hepatology. 1999;30(5):1302–1306. https://doi.org/10.1002/hep.
510300525
LDL-C low-density lipoprotein cholesterol
4. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir
LP lumbar puncture nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908. https://doi.
org/10.1155/2011/354908
LPV lopinavir 5. Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for
LPV/r lopinavir/ritonavir the HIV-treating clinician. South Afr J HIV Med. 2018;19(1):817. https://doi.
org/10.4102/sajhivmed.v19i1.817
MDRD modification of diet in renal disease 6. Cruciani M, Mengoli C, Malena M, et al. Virological efficacy of abacavir:
Systematic review and meta-analysis. J Antimicrob Chemother. 2014;
MVC maraviroc 69(12):3169–3180. https://doi.org/10.1093/jac/dku279
NGT nasogastric tube 7. D. A. D. Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse
transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients
NNRTI non-nucleoside reverse transcriptase inhibitor enrolled in the D:A:D study: A multi-cohort collaboration. Lancet. 2008;
371(9622):1417–1426. https://doi.org/10.1016/S0140-6736(08)60423-7
NRTI nucleoside reverse transcriptase inhibitor
8. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated
NTDs neural-tube defects with initial antiretroviral treatment containing abacavir: Short and long-term
results from ACTG A5001/ALLRT. Clin Infect Dis. 2011;52(7):929–940. https://
NtRTI nucleotide reverse transcriptase inhibitor doi.org/10.1093/cid/ciq244
NVP nevirapine 9. Majluf-Cruz A, Luna-Castanos G, Trevino-Perez S, Santoscoy M, Nieto-Cisneros L.
Lamivudine-induced pure red cell aplasia. Am J Hematol. 2000;65(3):189–191.
OI opportunistic infection https://doi.org/10.1002/1096-8652(200011)65:3<189::AID-AJH2>3.0.CO;2-6
PCR polymerase chain reaction 10. Cohen K, Viljoen C, Njuguna C, Maartens G. Emtricitabine-associated red cell
aplasia. AIDS. 2019;33(6):1095–1096. https://doi.org/10.1097/QAD.0000000
PI protease inhibitor 000002136
PI/r ritonavir-boosted ritonavir 11. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-
daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2
study): 96 week results from a randomised, double-blind, non-inferiority trial.
PMTCT prevention of mother-to-child transmission of HIV Lancet Infect Dis. 2013;13(11):927–935. https://doi.org/10.1016/S1473-
3099(13)70257-3
PPIs proton pump inhibitors
12. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine
PrEP pre-exposure prophylaxis for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818.
https://doi.org/10.1056/NEJMoa1215541
RAL raltegravir 13. Molina JM, Clotet B, Van Lunzen J, et al. Once-daily dolutegravir versus darunavir
RCTs randomised controlled trials plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO):
96 week results from a randomised, open-label, phase 3b study. Lancet HIV.
RIF rifampicin 2015;2(4):e127–e136. https://doi.org/10.1016/S2352-3018(15)00027-2
14. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in
RFB rifabutin antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48
RNA ribonucleic acid results from the randomised, double-blind, non-inferiority SAILING study. Lancet.
2013;382(9893):700–708. https://doi.org/10.1016/S0140-6736(13) 61221-0
RPV rilpivirine 15. You J, Wang H, Huang X, et al. Therapy-emergent drug resistance to integrase
strand transfer inhibitors in HIV-1 patients: A subgroup meta-analysis of clinical
RTV or /r ritonavir trials. PLoS One. 2016;11(8):e0160087. https://doi.org/10.1371/journal.
pone.0160087
sCr serum creatinine
16. Orrell C, Hagins DP, Belonosova E, et al. Fixed-dose combination dolutegravir,
sCrAg serum cryptococcal antigen abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir
disoproxil fumarate and emtricitabine in previously untreated women with
TAF tenofovir alafenamide HIV-1 infection (ARIA): Week 48 results from a randomised, open-label, non-
inferiority, phase 3b study. Lancet HIV. 2017;4(12):e536–e546. https://doi.
TAM thymidine analogue mutation org/10.1093/ofid/ofw194.89
TB tuberculosis 17. Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted
lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in
TB-IRIS tuberculosis immune reconstitution inflammatory adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): An
open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19(3):253–
syndrome 264. https://doi.org/10.1016/S1473-3099(19)30036-2
http://www.sajhivmed.org.za 55 Open Access